Last checked at 25 Sep 2014 11:03
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Synairgen Share News (SNG)
SNG Share
Price
SNG Share
News
SNG Share
Chat11
SNG Share
Trades16
SNG
Live RNS
SNG Share
Charts
SNG Level 2
Console
SNG Live
Share Price
SNG Broker
Ratings
SNG Directors
Deals
SNG Financial
Diary
SNG
Fundamentals
SNG Short
Positions
SNG
Media
Synairgen Information
Share Price Information for Synairgen (SNG)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
6.20
Bid:
5.52
Ask:
7.00
Change:
0.08 (1.31%)
Spread:
1.48 (26.812%)
Open:
6.20
High:
6.20
Low:
6.20
Prev. Close:
6.12
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Small caps round-up: Griffin Mining, Energy XXI
Thu, 06th May 2010 12:49
Griffin Mining posted a rise in profits in the year to December 31 despite a slide in revenues following the collapse in metals prices in late 2008.The company, which operates the Caijiaying zinc-gold mine in China, posted a pre-tax profit of $7.2m, up from $7m in 2008, even as revenues fell to $25.4m from $32.1m.Griffin said it shut down Caijiaying in the first half the year, which enabled it to improve the mine's efficiency once it re-opened in the second half and metals prices had recovered.Bermuda-based oil group Energy XXI saw third quarter earnings before interest, taxes, depreciation, depletion and amortization rise by a third from the same period a year ago to $87.3m.'This quarter's results benefitted from our December consolidation of interests in our key Gulf of Mexico shelf properties and reflect the advantage of having an oil-focused production portfolio,' chairman and chief executive John Schiller said.Investors have welcomed news that respiratory disease drug developer Synairgen's inhaled interferon beta (IFN-beta) to treat rhinovirus infections in asthma and chronic obstructive pulmonary disease (COPD) has been granted in Europe."The European patent grant and the US patent granted last year are key ingredients in the out-licensing package," said chief executive Richard Marsden.Deltex Medical, whose Oesophageal Doppler monitoring equipment is used to measure blood flow in surgery patients, has received a forward order for probes worth at least $204,000 over the next six months. The disposable probes, used with Deltex's CardioQ-ODM system, are placed into the oesophagus through either the mouth or nose and help calculate how quickly blood is flowing. A reduction in circulating blood volume can be deadly.South Africa-focused ferrochrome producer International Ferro Metals, which has its head office in Sydney, thinks it will not be affected by Australia's proposals for a supertax on mining companies.'As all of IFL's operations and resources are located in South Africa with no mining activities undertaken in Australia, IFL believes, having consulted with its advisors, that it will not be liable for the newly proposed resource rent tax,' it says. Personnel software provider Allocate Software has bought Dynamic Change, a compliance and performance management software developer focused on the UK healthcare market. Allocate will pay up to £9m over three years for Dynamic Change, with £4.9m in cash and £0.1m in shares being paid upfront. The company is being acquired with cash balances and receivables of around £1.6m, largely reflecting deferred income which arises from subscriptions paid annually in advance. Clapham House, the restaurant group that owns the Gourmet Burger Kitchen (GBK) brand, is to raise £2.2m from a placing of 3.73m shares at 60p each. The funds will be used to accelerate the expansion of the GBK chain.Product development software specialist Sopheon has sealed 12 new and extension licence orders so far in 2010. Since the company's last trading update on 24 March revenue visibility for the full year from contracted business and recurring revenue streams has risen to £5.6m from £4.8m.
More News
4 Jul 2014 12:11
Synairgen raises funds to develop AstraZeneca drug
Synairgen has placed 12.2m shares to raise funds for the assessment and preparation of SNG001, the drug recently licensed from AstraZeneca, across five projects that it has identified as the most suitable direction for its development. The drugs company raised around £5.3m before expenses after is
Read more4 Jul 2014 07:21
15 Jun 2014 12:28
Sunday share tips: Whitbread, Petra Diamonds, Empiric Student Property
Whitbread looks like a reliable investment despite the imminent departure of Chairman Anthony Habgood, Matthew Goodman said in the Sunday Times's Inside the City column. The company was a mess when Habgood took over in 2005 but he has sold peripheral businesses to focus on Premier Inn and Costa Coff
Read more12 Jun 2014 16:37
MARKET COMMENT: FTSE 100 Closes Slightly Higher Amid Iraqi Tensions
LONDON (Alliance News) - The FTSE 100 closed fractionally higher Thursday, having spent the day trading within a tight range, with oil and gas exploration and production company BG Group leading the gains as the price of oil climbed amid escalating violence in Iraq.
Read more
12 Jun 2014 10:23
TOP NEWS: Discount Retailer B&M Prices Biggest London IPO Of 2014
LONDON (Alliance News) - The following is a summary of top news stories Thursday.
----------
COMPANIES
----------
The initial public offering of B&M European Value Retail SA, the discount retailer chaired by former TescoRead more
12 Jun 2014 08:25
London open: Mining stocks pull FTSE 100 lower ahead of data
- Profit taking continues as miners fall - Traders await global economic data - Broker downgrades hit blue chips techMARK 2,839.63 -0.04% FTSE 100 6,827.09 -0.17% FTSE 250 16,073.58 -0.09% UK stocks opened flat on Thursday morning as weakness in the mining sector held back any chances of a rebound
Read more12 Jun 2014 07:42
AstraZeneca signs licence deal with Synairgen
British drugs maker AstraZeneca has signed a licence agreement with AIM-listed Synairgen for the development of SNG000l, a treatment for respiratory tract viral infections in patients with severe asthma. Under the deal, FTSE 100-listed Astra will pay Synairgen a $7.25m up-front fee and potential de
Read more12 Jun 2014 07:36
UK MORNING BRIEFING: AstraZeneca Signs Asthma Deal With Synairgen
LONDON (Alliance News) - UK shares have opened flat Thursday, following negative trading in the US and Asia overnight.
AstraZeneca is the third biggest gainer on the FTSE 100. The drugmaker said it has signed a global licence agreement with AIM-listed biotechnology
12 Jun 2014 06:52
AstraZeneca Licences Asthma Exacerbation Treatment From Synairgen
LONDON (Alliance News) - AstraZeneca PLC said Thursday that it had signed a global licence agreement with AIM-listed biotechnology company Synairgen PLC for its SNG001 compound for the treatment of infections that exacerbate asthma. The compound is used to treat respiratory tract infections
Read more20 Mar 2014 12:47
Synairgen Pretax Loss Narrows On Expenses
LONDON (Alliance News) - Synairgen PLC Thursday said its pretax loss narrowed in its full year 2013 as administrative expenses fell during the period. The respiratory drug discovery and development company said its pretax profit narrowed to GBP2.3 million from GBP2.5 million the previous ye
Read more5 Mar 2014 11:31
Synairgen Jumps As It Raises Cash While Progressing Licensing Talks
LONDON (Alliance News) - Synairgen PLC Wednesday said it has raised GBP1.5 million by placing 3.1 million shares at 48 pence each, money it will use for working capital while it progresses current licensing discussions through to a conclusion. In a statement, the respiratory drug discovery
Read more5 Mar 2014 08:31
UK MORNING BRIEFING: Standard Chartered Profits Fall, Cuts Bonus Pool
LONDON (Alliance News) - Shares have opened mostly lower Wednesday with small-caps out-performing large caps, following Tuesday's relief rally from lowered Ukraine tensions.
Standard Chartered has reported lower 2013 profit and a 15% reduction in its bonus pool, whi
5 Dec 2012 11:10
Synairgen reports 'significant progress'
Synairgen, a respiratory drug discovery and development company, has reported 'significant progress' since the end of June. The firm said that discussions with potential licensing partners for its SNG001 product have progressed, the company has engaged with the US government to investigate the pote
Read more